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Abstract
Eight carriers of the A3243G mutation of mitochondrial DNA without stroke-
like episodes were monitored for up to 7 years in clinical and metabolic stud-
ies, by magnetic resonance imaging (MRI) and positron emission tomography
(PET). None developed mitochondrial encephalopathy (MELAS), but 2 devel-
oped diabetes mellitus, 1 terminal kidney failure and 2 cardiomyopathy.
One patient improved markedly under ubiquinone. Electroencephalography
showed progressive slowing in 2 cases, but electrophysiological tests and MRI
were otherwise noncontributary. PET showed widespread cortical and basal
ganglion metabolic deficits in 6 cases. We conclude that internal medical com-
plications are more common than MELAS in adult carriers of the mutation.
PET findings, firstly reported in such patients, suggest that chronic subclinical
encephalopathy is very frequent, and PET may play a role in monitoring in the
future.
OOOOOOOOOOOOOOOOOOOOOO
Introduction
An A-G transition mutation at nucleotide position
3243 of mitochondrial DNA (mtDNA) is the most com-
mon cause of mitochondrial encephalopathy, lactic acido-
sis, and stroke-like episodes (MELAS) [1, 2]. Recent stud-
ies have shown that chronic progressive external ophthal-
moplegia, diabetes mellitus and renal disease can be
caused by the same mutation, and that many carriers of
the mutation have only minor symptoms [3, 4]. It remains
unknown to what extent oligosymptomatic patients will
develop MELAS or any other serious disorder, how close-
ly or by what method carriers of the mutation at nucleo-
tide position 3243 should be monitored, and when they
should be treated with enzyme substitution such as ubi-
quinone. We addressed this problem by following 8 car-
riers of the mutation without strokes closely for 2–6 years
to identify the best monitoring protocol.
Patients and Methods
In this study all patients called our attention after maternal rela-
tives developed MELAS due to a point mutation at nucleotide posi-
tion 3243 of mtDNA. Patients 1–6 are members of a pedigree carry-
ing the mtDNA 3243 mutation described elsewhere [3]. Their clini-
cal features are summarized in table 1. Patient 8, who was unrelated
to the others, developed chronic progressive external ophthalmople-
gia and myopathy at age 38 (table 1).
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Table 1. Clinical findings
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8
Age at
diagnosis 18 15 38 26 32 21 29 41
Sex female male male male male male female female
Year of
diagnosis
1989 1989 1993 1993 1993 1993 1994 1992
Previous
symptoms
short stature
acute remitting
deafness
short stature none exercise
intolerance
hyperuricemia hearing loss
hypoglycemic
episodes
hearing loss myopathy
hearing loss
Findings
at
diagnosis
mild proteinuria
lactic acidosis
mild deafness
mild deafness
lactic acidosis
proteinuria
mild deafness
retinopathy
lactic acidosis discrete
hearing loss
hyperuricemia
moderate
deafness
mild deafness
proteinuria
CPEO, mild
tetraparesis
mild deafness
lactic acidemia
Treatment ubiquinone
since 1991
ubiquinone
since 1991
ubiquinone
since 1993
ubiquinone
since 1993
ubiquinone
since 1993
none none ubiquinone
since 1992
Course severe deafness
1990
IDDM 1993
episodic ab-
dominal pain
renal failure
since 1993
progressive
deafness
unchanged improvement
of exercise
intolerance
unchanged acute hearing
loss 1993
unchanged improvement
of exercise
intolerance
Findings
at
follow-up
IDDM
deafness
cardiomyopathy
nephropathy
mild deafness
renal failure
cardiomyopathy
unchanged unchanged unchanged deafness
NIDDM
unchanged tetraparesis
improved,
otherwise
unchanged
IDDM = Insulin-dependent diabetes mellitus; NIDDM = non-insulin-dependent diabetes mellitus; CPEO = chronic progressive external ophthalmoplegia.
The study protocol included a physical examination, blood bio-
chemistry, urinalysis, bicycle exertion tests, glucose tolerance testing,
audiometric, ophthalmologic and cardiological examinations. An
electroencephalogramm (EEG), visual evoked potentials, brainstem
acoustic evoked potentials, somatosensory and motor evoked poten-
tials were performed according to standard procedures. Magnetic res-
onance imaging (MRI) was done on a 1.5-tesla Siemens Magnetom
using T1 (TR 600 ms/TE 15 ms) and T2-weighted (TR 3,460 ms/TE
120 ms) spin echo sequences with axial and sagittal 4-mm slices.
Complete follow-up was every 2 years, and physical examinations,
blood tests and EEG were performed every 6 months. Positron emis-
sion tomography (PET) was done on a Siemens ECAT Exact 47 scan-
ner (FOV 16.2 cm) in a dimly lit, quiet room after 12 h fasting. After
30 min of rest, a rapid bolus of 18F-fluorodeoxyglucose (mean 4.7 B
2.11 MBq per kg body weight) was injected. Dynamic scanning
started immediately with 10 scans of 30 s, 3 scans of 300 s and 7
scans of 600 s, in all 90 min. Images were reconstructed by filtered
back-projection using a Hann filter (cutoff frequency 0.45 mm !
101). Attenuation correction was calculated before using an automat-
ic software procedure (CTI, Knoxville, Tenn., USA). Quantitative
metabolic rates of glucose (CMRglc) were calculated using the Patlak
graphical method [5], and the metabolic rates (CMRglc) of eight
regions of interest of 1-cm thickness calculated according to the tem-
plate published by Herholz [6]. The regions of interest represented
prefrontal, temporal, temporoparietal, parietal, sensorimotor and
visual cortex, basal ganglia and cerebellum on each side. A variation
of 110% in CMRglc from one cortical area to another or a decrease
of 110% in global cortical CMRglc in one area was considered patho-
logical.
Muscle biopsies were obtained from the left biceps brachii muscle
in all cases. Frozen sections were stained with hematoxylin and eosin,
modified trichrome, periodic acid-Schiff, NADH and succinate de-
hydrogenase phosphorylase, ATPase (pH 9.4) and oil-red for light
microscopy. Electron microscopy was performed from glutaralde-
hyde-fixed material stained with osmium tetroxide. Biochemical
studies of respiratory chain activity were performed from homoge-
nized muscle as described previously [7]. Genomic DNA was iso-
lated from lymphoblasts and from 50 Ìg of frozen muscle tissue for
molecular analysis as reported [3, 8]. The percentage of mutant
mtDNA was estimated by quantitative RFLP analysis according to
Seibel et al. [9]. DNA was amplified and the PCR reaction mixture
supplemented with 32P-labeled dATP after 29 cycles. An additional
amplification cycle was carried out. Quantitative Apa I-RFLP analy-
sis was performed and radioactively labeled products were quanti-
tated by scintillation counting.
Results
Table 2 shows paraclinical data and imaging results.
Bioptic, biochemical and molecular results are shown in
table 3. None of the patients developed stroke-like epi-
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Table 2. Paraclinical findings
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8
Electrophysiology
At
diagnosis
AEP: deformed
waves I and II
others normal
normal normal normal EEG: mild
generalized
slowing
others normal
normal normal EEG: mild
generalized
slowing
During
follow-up
EEG:
mild slowing
EEG: mild
generalized
slowing
normal normal unchanged normal normal unchanged
MRI
At
diagnosis
cerebellar
hypoplasia
normal not done
(claustrophobia)
CT: normal
normal normal normal cerebellar
atrophy
normal
During
follow-up
unchanged
(1994)
normal
(1994)
normal punctate
periventricular
hyperintensity
normal unchanged normal
PET:
regional
glucose
metabolic
deficits
cerebellar
deficit
otherwise
normal
basal ganglia
right temporal
and visual
cortex deficits
parietal defect
(minimal)
basal ganglia
and visual
cortex deficits
motor and
parietal cortex
hypometabolism
markedly reduced
unhomogeneous
parietal, motor,
and right temporal
cortex
motor, parietal
and temporal
cortex deficits
mild parieto-
occipital cortex,
basal ganglia
and cerebellar
hypometabolism
AEP = Auditory evoked potential.
Table 3. Bioptic and molecular findings
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Normal
values
Muscle biopsy
LM mild lipid
storage
normal mild lipid
storage
moderate
lipid storage
normal normal normal RRF
EM deformed
mitochondria
increased
in lateral
sarcoplasm
rarely deformed
mitochondria,
increased mito-
chondria in lateral
sarcoplasm
normal mild increase
in lipid
normal normal moderate
increase in
mitochondria
massive,
deformed
mitochondria
paracristalline
inclusions
Respiratory chain activities, U/g muscle
ND 54 78 37.5/4.6* 34.6/8.2* 20.2/2.6* 33.5/4.2* 65.4/0.4* 32.4 48B9.4
NC 7.3 12 2.0/1.3* 2.6/1.4* 1.2/0.8* 2.6/1.8* 4.8/3.4* 6.5 3.2B1.5
SD 2.6 3.6 2.2 1.6 1.7 2.6 1.0 2.05 2.4B1.1
SC 3.3 4.5 1.4 1.9 0.9 2.2 1.4 1.5 1.6B0.6
COX 2.3 3.4 2.5 2.9 1.4 3.7 4.7 5.1 2.8B1.0
Citrate synthetase 7.8 9.7 5.3
Molecular analysis
Percent mutant
mtDNA in blood
49 60 17 23 10 15 17 14
Percent mutant
mtDNA in muscle
83 72 42 63 31 23 positive
(not quantified)
77
RRF = Ragged-red fibers; LM = light microscopy; EM = electron microscopy; ND = NADH dehydrogenase;
NC = NADH cytochrome c reductase; * = + rotenone; SD = succinate dehydrogenase;
SC = succinate/cytochrome c reductase: COX = cytochrome c oxidase.
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Fig. 1. PET, axial images. Patient 2. a, b Reduced CMRglc in the
occipital cortex. c, d Inhomogeneous glucose utilization in the basal
ganglia, the caudate nuclei being particularly involved. e, f Reduced
right temporal CMRglc.
sodes, but patients 1 and 6 suffered episodes of acute
hearing loss, which might possibly represent a ‘stroke’ of
the cochlea. Following treatment with 150 mg ubiqui-
none/day, exercise tolerance improved in patients 4 and
8, remained unchanged in patients 3 and 5, but patients 1
and 2 developed severe medical complications. Without
treatment, patient 6 worsened and patient 7 was un-
changed. MRI findings changed minimally only in pa-
tient 5. The most common finding on PET was an asym-
metrical bilateral reduction in parietal cortical CMRglc
(patients 2, 3, and 5–7, fig. 1). Patient 6 had the most
marked abnormalities of CMRglc.
Respiratory chain studies revealed increased mito-
chondrial volume in patients 1 and 2 without a specific
defect, and mild carnitine deficiency in patient 1. Pa-
tient 7 had low normal complex II activity, but normal
succinate dehydrogenase stain light microscopically. The
others had low NADH dehydrogenase activity, compat-
ible with a complex I defect; patient 5 also had low succi-
nate-cytochrome c reductase activity, suggesting an addi-
tional complex III defect. Patients 1 and 2 had the highest
percentages of mutant mtDNA, patients 4 and 8 showed
marked heteroplasmy comparing blood and muscle, and
the others had generally low (!50%) percentages of mu-
tant mtDNA.
Discussion
MELAS is generally an early-onset syndrome that rap-
idly causes severe neurological deficits and typically
stroke-like episodes associated with an A-G point muta-
tion of mtDNA at nucleotide position 3243. Recently,
internal medical conditions, such as diabetes mellitus,
cardiomyopathy or kidney failure, have gained attention,
either complicating MELAS or on their own [3, 4, 10, 11]
in association with the A3243G mutation, which may be
an important cause of diabetes mellitus in some popula-
tions [12–14]. However, a growing number of asymptom-
atic or only mildly affected gene carriers have been recog-
nized, and it is at present impossible to determine which
carriers will progress to the full-blown syndrome. Clinico-
genetic correlations are difficult due to heteroplasmy and
because the precise mechanism of the disease caused by
the rRNA Leu(UUR) point mutation remains unclear.
Asymptomatic patients generally have lower percentages
of mutant mtDNA in blood than classical MELAS cases,
but this is not a close correlation [3, 4, 15]. The optimal
management of presymptomatic carriers has not been
defined, because the efficacy of any treatment is unproved
[16]. Until now there are few PET studies in mitochon-
drial encephalopathies [17–20]. Frackowiak et al. [17]
showed uncoupling of cerebral oxygen (CMRO2) and
CMRglc with preferential depression of the cerebral met-
abolic rate of oxygen in 4 patients with mitochondrial
encephalopathy and complex I deficiency, but without
MELAS. Duncan et al. [20] recently demonstrated accel-
erated CMRglc in 1 child with complex I and 1 with com-
plex IV deficiency. Both had increased cerebral lactate on
MR spectroscopy. Yokoi et al. [19] showed decreased
aerobic pyruvate turnover, reduced cerebral blood flow
and CMRO2 in 6 patients with mitochondrial encephalo-
myopathies (2 complex III, 3 complex IV deficiencies, no
stroke-like episodes). The data are difficult to compare, as
the patients were examined at different stages of their dis-
ease, had varying defects in the respiratory chain, and
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mtDNA mutations were mostly not defined. Interesting-
ly, Castillo et al. [21] reported no basal ganglia involve-
ment in 8 MELAS patients using MR spectroscopy, con-
trary to our PET findings.
None of our patients showed clinical signs of cerebral
involvement at diagnosis. Electrophysiological studies
were of limited value for follow-up, only revealing mild
generalized EEG slowing in patients 5 and 8, and de-
formed brainstem acoustic evoked potentials in patient 1.
MRI did not show major pathology in our patients with-
out cerebral symptoms. Muscle biopsy showed ragged-red
fibers only in patient 8, but mild-to-moderate lipid stor-
age more frequently (patients 1, 3 and 4). Respiratory
chain studies most often detected complex I defects.
Patients 4 and 8 had 150% mutant mtDNA in muscle
despite low percentages in blood and were the only ones
with myopathy. However, patients 1 and 2 had even more
mutant mtDNA in both muscle and blood, but no muscu-
lar symptoms; their follow-up revealed a more severe oxi-
dative disorder than in the other patients, as they were the
only ones to develop serious internal medical disorders.
Probably patients with 150% mutant mtDNA in several
different tissues are at a higher risk of serious disease at an
earlier age [3, 15], so a muscle biopsy can help estimate
prognosis. The effect of treatment remains unproven;
patients with or without treatment remained unchanged,
or progressed. Myopathy seemed to be improved by ubi-
quinone. Our study shows that routine follow-up must
include blood tests, EKG and EEG, but other electrophys-
iological studies and MRI are probably of little value
without specific symptoms.
PET revealed widespread abnormalities in 6 patients,
with a pattern differing from vascular disorder and from
neurodegenerative disorders such as Alzheimer’s or Par-
kinson’s disease [6, 22]. CMRglc defects were often pat-
chy or asymmetrical, and involved cortex and deep gray
matter. The parietal cortex was most often involved, the
basal ganglia next. The prefrontal cortex was never in-
volved. Normal absolute values of CMRglc are still a mat-
ter of debate, and for ethical reasons we did not examine a
normal control group. However, other workers have dem-
onstrated that under normal conditions intraindividual
variations of CMRglc in cortex are very small [23, 24], so
we feel that that our observed inhomogeneous CMRglc in
gray matter (110% variation) are truly pathological. Our
findings were too heterogeneous to suggest a systematic
predilection for a particular area of the brain, contrary to
stroke-like lesions, which are very often occipital [25, 26].
The visual cortex was not very frequently involved in our
series, which raises the question whether such PET abnor-
malities are related to stroke-like episodes at all. The
pathogenetic mechanisms of cerebral metabolic abnor-
malities cannot be adequately studied without measure-
ment of oxygen consumption, which revealed uncoupling
of glucose metabolism with reduced oxygen consumption
per molecule of glucose in the study by Frackowiak et al.
[17]. Further study is therefore needed to determine the
significance of pathological CMRglc. An interesting paral-
lel might be drawn between reduced CMRglc in the basal
ganglia and the cerebral pathology of 2 other members of
the family who were autopsied [27]. Their basal ganglia,
especially the globus pallidus, showed disseminated mi-
crocalcification at an early age (fig. 2) which was not seen
Fig. 2. HE-stained light-microscopic autopsy section of the glo-
bus pallidus in a 10-year-old MELAS patient, a sister of patients 1
and 2. Disseminated microcalcification (arrows), possibly correlating
to basal ganglion hypermetabolism on PET.
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elsewhere in the brain and suggests a chronic degenerative
process which could be related to hypometabolism on
PET. Thus even in oligosymptomatic patients with nor-
mal MRI, cerebral metabolism is markedly abnormal.
Long-term follow-up is needed to define the prognostic
value of PET. Such patients should be considered at risk
of developing acute symptoms, especially in situations
that raise the cerebral metabolic demand, such as sei-
zures, or reduce the supply of substrate. MR spectroscopy
can directly show regional mitochondrial metabolism,
expressed in lactate levels [20, 28]. This cannot be done by
PET, which studies mainly extramitochondrial glucose
metabolism; on the other hand, the precise clinical rele-
vance of increased lactate is unknown, and PET might
help provide a rationale for treatment without waiting for
strokes. PET may also play a role in assessing treatment
regimens in future studies.
In conclusion, our follow-up study of carriers of the A-
G transition at nucleotide position 3243 of mtDNA with-
out stroke-like episodes showed that patients with the
mutation can remain neurologically stable over long peri-
ods, but frequently develop serious internal medical dis-
orders. This underlines the importance of an early detec-
tion of carriers of the mutation by an adequate follow-up
including a neurological, general medical and audiomet-
ric examination, blood chemistry, urinalysis, EKG and
EEG. A high percentage of mutant mtDNA in several tis-
sues may be associated with an unfavorable prognosis, but
in many patients PET reveals abnormalities, most often
involving the basal ganglia and parietal cortex, before
structural damage occurs.
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Prize for the Promotion of New Acquisitions
in Ageing Psychotherapy
A 5,000-DEM prize for the promotion of new acquisitions in ageing psychotherapy will be
awarded by the Arbeitsgruppe für Psychotherapie im Alter (Working Group for Ageing Psy-
chotherapy) for outstanding scientific work in ageing psychotherapy (theory, treatment, care).
The prize may be split. Applications should be submitted in the proper form until March 31,
1998 to:
Arbeitsgruppe für Psychotherapie im Alter
Prof. Dr. Dr. R.D. Hirsch
Gerontopsychiatrisches Zentrum
Rheinische Kliniken
Kaiser-Karl-Ring 20
D–53111 Bonn (Germany)
